Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track VRTX with free AI briefings, catalyst countdowns, and dilution alerts.

VRTX · Vertex Pharmaceuticals Incorporated

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$9.8B Cash on Hand
CF+ Cash Runway
2.1% Short Interest
$595.36 Analyst Target (28)
Follow VRTX by email Get an email when VRTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about VRTX, unsubscribe in one click. Privacy

📣 What VRTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Suzetrigine
FDA approved Jan 2025 · Journavx
Acute Pain Phase 4 · NCT06887959 Completed
Ivacaftor
FDA approved Jan 2012 · Kalydeco
Cystic Fibrosis Phase 3 · NCT06460506 Active not recruiting
Tezacaftor Cystic Fibrosis Phase 3 · NCT05422222 Active not recruiting
Povetacicept Primary Membranous Nephropathy Phase 2/3 · NCT07204275 Recruiting
multimodal analgesia regimen without suzetrigine Opioid Consumption, Postoperative Phase 3 · NCT07654296 Recruiting
Vanzacaftor Cystic Fibrosis Phase 3 · NCT05844449 Enrolling by invitation
VX-017 Diabetes Mellitus, Type 1 Phase 3 · NCT04786262 Recruiting
VX-147 Proteinuric Kidney Disease Phase 2/3 · NCT05312879 Active not recruiting
Exagamglogene Autotemcel (CTX001) Sickle Cell Disease Phase 2/3 · NCT03745287 Completed
Elexacaftor Cystic Fibrosis Phase 3 · NCT06460506 Active not recruiting
Zimislecel (VX-880) Diabetes Mellitus, Type 1 Phase 3 · NCT04786262 Recruiting
VX-993 Diabetic Peripheral Neuropathic Pain Phase 2 · NCT06619860 Recruiting
VX-264 Type 1 Diabetes Phase 1/2 · NCT05791201 Active not recruiting
VX-407 Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 2 · NCT07161037 Active not recruiting
VX-522 mRNA therapy Cystic Fibrosis Phase 1/2 · NCT05668741 Completed
VX-670 Myotonic Dystrophy Type 1 (DM1) Phase 1/2 · NCT06185764 Active not recruiting

Also used in these trials (approved or third-party drugs, not VRTX's own candidates): Sibeprenlimab, Pregabalin, Tacrolimus Extended-Release, Efavirenz, Itraconazole, Midazolam Hydrochloride.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

VRTX holds $9.8B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VRTX files for a raise →

👥 Who Owns VRTX

Insiders 0.1% Institutions (2490 holders) 98.4% Public and other holders 1.5%
HolderTypeShares% of sharesAs of
Capital World Investors Institution (13G, 5%+) 25,695,015 10.13% 2026-03-31
Blackrock Inc. Institution (13F) 23,803,111 9.39% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 19,036,076 7.51% 2026-03-31
Capital Research Global Investors Institution (13G, 5%+) 17,821,661 7.03% 2026-09-30
State Street Corporation Institution (13F) 12,024,456 4.74% 2026-09-30
Invesco Ltd. Institution (13F) 8,280,998 3.27% 2026-09-30
Geode Capital Management, LLC Institution (13F) 6,081,969 2.40% 2026-09-30
JPMORGAN CHASE & CO Institution (13F) 5,691,686 2.24% 2026-09-30
Capital International Investors Institution (13F) 5,059,186 2.00% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 4,944,618 1.95% 2026-09-30
Reshma Kewalramani
CEO & President, Director
Insider 86,471 0.03% 2026-11-06
Amit Sachdev
EVP Chief Patient & Ext Af Off
Insider 74,031 0.03% 2026-07-21

Share count 253,537,674 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-12
filed 2026-11-16
WAGNER CHARLES F JR
Sale (S) 15,286 $547.87 31,764
2026-11-06
filed 2026-11-10
Kewalramani Reshma
Sale (S) 11,866 $531.53 86,471
2026-10-20
filed 2026-10-22
Brennan Daniel J.
Award (A) 795 $503.47 795
2026-09-08
filed 2026-09-10
van Grunsven Jasper
Award (A) 8,682 – 8,682
2026-08-28
filed 2026-09-01
Ambrose Kristen
Award (A) 5,000 – 11,624

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full VRTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VRTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.